Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,146.90 -32.21 (-2.73%)

Official Closing Price Updated: 6:30 PM EDT, Jul 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table? ↗

Today 14:30 EDT

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Via The Motley Fool

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead? ↗

Today 13:50 EDT

Beam Therapeutics' growing pipeline could reward patient investors.

Via The Motley Fool

For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026? ↗

Today 11:04 EDT

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

Via The Motley Fool

Topics ETFs

Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setup ↗

July 17, 2026

Via Chartmill

Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026? ↗

Today 10:37 EDT

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

Via The Motley Fool

Topics ETFs

PJP vs. IYH: Which Healthcare ETF Is the Better Buy? ↗

Today 6:59 EDT

PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.

Via The Motley Fool

Topics ETFs

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗

Today 3:35 EDT

It is definitely a strong contender.

Via The Motley Fool

Topics Intellectual Property

Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years ↗

July 19, 2026

Maybe you should, too.

Via The Motley Fool

IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? ↗

July 19, 2026

BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.

Via The Motley Fool

Topics ETFs

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors? ↗

July 18, 2026

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Via The Motley Fool

Topics ETFs

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗

July 18, 2026

Viking's latest program seeks to push the envelope in weight loss efficacy.

Via The Motley Fool

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Via The Motley Fool

Topics ETFs

The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗

July 17, 2026

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

Via The Motley Fool

Topics Intellectual Property

Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗

July 17, 2026

Novo Nordisk is finally getting one up on its biggest rival.

Via The Motley Fool

Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternatives ↗

July 17, 2026

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.

Via Benzinga

Why AtaiBeckley Stock Soared Today ↗

July 16, 2026

The psychedelic drugmaker is being acquired.

Via The Motley Fool

Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion ↗

July 16, 2026

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.

Via The Motley Fool

Topics Government Stocks

This GLP-1 Stock Could Double by 2030. Here's Why ↗

July 16, 2026

Investors need to ask tough questions before initiating a position in this biotech company.

Via The Motley Fool

Why Is GH Research Stock Trading Higher on Thursday? ↗

July 16, 2026

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.

Via Benzinga

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal ↗

July 16, 2026

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

Via Benzinga

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗

July 16, 2026

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Via The Motley Fool

Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF ↗

July 16, 2026

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.

Via The Motley Fool

Topics ETFs

Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover ↗

July 16, 2026

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.

Via Investor's Business Daily

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗

July 16, 2026

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Via The Motley Fool

Topics ETFs

Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’ ↗

July 16, 2026

Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.

Via Benzinga

The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? ↗

July 16, 2026

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.

Via Investor's Business Daily

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED) ↗

July 16, 2026

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.

Via Benzinga

If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today ↗

July 15, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Why Vivosim Labs Shares Are Rocketing on Wednesday? ↗

July 15, 2026

VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.

Via Benzinga

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech ↗

July 15, 2026

With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.